TON March 2016 Vol 9 No 2

Providing Care for the Whole Patient: Sexuality and Cancer
The Oncology Nurse-APN/PA spoke with Anne Katz, PhD, RN, FAAN, about her chosen career as a certified Sex Counselor at CancerCare Manitoba and Clinical Nurse Specialist at the Manitoba Prostate Centre in Canada. Read More ›

Acute Myeloid Leukemia: Understanding the Patient’s Experience
Patients with acute myeloid leukemia (AML) often feel blindsided by their diagnosis, have trouble understanding their treatment choices, and suffer symptoms that are inadequately addressed. This is a patient population with sizable, and unmet, palliative care and psychosocial needs. Read More ›

Conference News
Here is a review of study results of various medications being reported from different conferences. Read More ›

Beth Faiman Nominated for Leukemia & Lymphoma Society Woman of the Year
In a recent interview with The Oncology Nurse-APN/PA (TON), Beth Faiman, PhD, APRN-BC, AOCN, Nurse Practitioner, Cleveland Clinic Taussig Cancer Institute, OH, and Editor-in-Chief of TON discussed her recent acceptance of a nomination for the Leukemia & Lymphoma Society (LLS) Woman of the Year award. Read More ›

An interactive text messaging tool to assess adherence to adjuvant endocrine therapy for breast cancer and to deliver direct communication to providers was found helpful by the majority of patients. Read More ›

Both abiraterone and enzalutamide are approved by the US Food and Drug Administration for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Both drugs have different mechanisms of action and different adverse event profiles, but there are limited data comparing them directly. Read More ›

Regular use of aspirin appeared to reduce the risk for dying from lethal prostate cancer in a large observational study reported at the 2016 Genitourinary Cancers Symposium. Read More ›

Docetaxel added to androgen-deprivation therapy (ADT) improves survival for men with metastatic hormone-sensitive prostate cancer (mHSPC), as shown by the pivotal ECOG 3805 CHAARTED trial. Read More ›

Men with low-risk prostate cancer are typically offered management with active surveillance, which entails regular office visits, digital rectal exam, MRI scans, prostate-specific antigen (PSA) testing, and prostate biopsy at physician-specified intervals. Read More ›

Page 1 of 2

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: